• POISE has shown how perioperative ß-blockers may increase the risk of death and stroke at 30-day follow-up by increasing the risk of clinically significant hypotension.
D
uring the last few decades, substantial advances in noncardiac surgery have improved the treatment of disease and the quality of life for patients. As a result, the number of patients undergoing noncardiac surgery is growing. A recent study that used surgical data from 56 countries suggests that 200 million major noncardiac surgical procedures are undertaken annually around the world. 1 Noncardiac surgery is associated with major vascular complications (i.e., vascular death, nonfatal myocardial infarction (MI), nonfatal cardiac arrest, and nonfatal stroke). Worldwide each year, 3-5 million adult patients have a perioperative vascular complication in the first 30 days after surgery, 2 a number similar to the annual global incidence of new patients acquiring HIV. 3 Despite the magnitude of this public health problem, there has existed a paucity of adequately powered randomized controlled trials that have evaluated interventions that may lower the risk of major perioperative cardiovascular events. Because of this gap, a team of Canadian investigators led a large international randomized controlled trial evaluating the effects of a ß-blocker in patients undergoing noncardiac surgery. This trial was called the Perioperative Ischemic Evaluation (POISE) trial, and the primary results from this trial received fast-track publication in the Lancet in May, 2008. 4 
Rationale for the POISE trial
Two small randomized controlled trials (312 patients in total), which were published in the 1990s and had important methodologic limitations (i.e., they were unblinded, they were stopped early for unexpectedly large treatment effect in the setting of few events, and there was a failure to follow the intention-to-treat principle), suggested that ß-blockers given around the time of noncardiac surgery resulted in a 90% relative risk reduction in the composite outcome of cardiovascular death and nonfatal MI at the 30-day follow-up and a 55% relative risk reduction in death at the two-year follow-up. 5, 6 Primarily based on the results of these two trials, the American College of Physicians and the American College of Cardiology/American Heart Association perioperative guidelines recommended giving a ß-blocker to at-risk patients undergoing noncardiac surgery. 7, 8 More recently, two moderately sized randomized controlled trials (1417 patients in total), which avoided the methodological limitations of the previous trials, did not show a benefit with perioperative ß-blockers. 9 Special report CMAJ • Worldwide, over 200 million adults have major noncardiac surgery each year, and several million experience a major vascular complication (i.e., vascular death, nonfatal myocardial infarction, nonfatal cardiac arrest or nonfatal stroke).
• For over a decade, guideline committees had recommended that at-risk patients receive a perioperative ß-blocker based on the results of two small trials with methodologic limitations.
• The POISE Trial, led by Canadian investigators, included 8351 patients from 190 centres in 23 countries; the trial showed that, although metoprolol CR prevented perioperative myocardial infarction, it increased the 30-day risk of total mortality and stroke.
recommend that physicians give ß-blockers to patients undergoing non cardiac surgery.
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Description of POISE
The POISE trial included 8351 patients from 190 hospitals in 23 countries, and 99.8% of the patients completed the 30-day follow-up. Patients, health care providers, data collectors and outcome adjudicators were blind to treatment allocation, and all analyses followed the intention-to-treat principle.
Patients were randomized to treatment with extended-release metoprolol succinate (metoprolol CR) or placebo starting two to four hours before surgery and continuing for 30 days. The goal was to administer 200 mg of the study drug (i.e., metoprolol CR or matching placebo) daily, but patients had to have a systolic blood pressure greater than or equal to 100 mm Hg and a heart rate greater than or equal to 50 beats/min to receive the study drug. Although the POISE trial was an international effort, the Canadian investigators (a multidisciplinary group of anesthesiologists, surgeons and specialists in internal medicine) were responsible for originating the idea for the trial, conducting the POISE pilot study, writing the POISE protocol, obtaining funding for the trial through a grant from the Canadian Institutes of Health Research (CIHR), developing the international collaboration of 190 centres in 23 countries, recruiting 3548 of the 8351 patients, doing the analyses, and writing the papers describing the POISE methods and main results. 
What we learned from POISE
POISE has provided many important insights into vascular complications among patients undergoing noncardiac surgery. POISE was the first trial to demonstrate a statistically significant increase in death and stroke with a perioperative ß-blocker. These results almost did not come to light because the POISE investigators encountered substantial opposition to this trial from many physicians who believed that perioperative ß-blockers were beneficial and without any substantial risks. Post-hoc multivariable analyses were done to determine population attributable risks, which represent the proportion of all outcomes attributable to the relevant risk factor if causality were proven. Clinically significant hypotension had the largest population attributable risk (37.3%) for death and the largest intraoperative/postoperative population attributable risk (14.7%) for stroke. Furthermore, for the outcome of death, the population attributable risk associated with perioperative stroke was 8.0%; with clinically significant bradycardia, the risk was 7.9%. Therefore, perioperative clinically significant hypotension, bradycardia and stroke caused by perioperative treatment with a ß-blocker potentially accounted for over 50% of the deaths seen during the POISE trial. Although clinically significant hypotension was an important predictor of perioperative stroke, our analysis explained fewer than half of the strokes. It is possible that more hypotension occurred that was clinically relevant but that did not fulfill our definition, and that this hypotension contributed to the higher incidence of stroke.
Two-thirds of the POISE patients who had a perioperative MI did not experience ischemic symptoms. We believe this occurred because about 75% of the MIs happened during the first 48 hours after surgery when most patients are receiving high doses of analgesic medications. The MIs without ischemic symptoms were independent predictors of death at the 30-day follow-up (HR 3.45, 95% CI 2.20-5.41). This finding shows the benefit of moni-toring troponins (part of the POISE protocol) for the first three days after surgery.
Future directions
POISE has resulted in several new studies that are being led by the Canadian POISE investigators. The Vascular Events In Noncardiac Surgery Patients Cohort Evaluation (VISION) Study is a prospective cohort study of 40 000 patients undergoing noncardiac surgery in several countries around the world, and more than 20 000 participants have already been recruited (for further information, please see www. clinicaltrials. gov, identifier no. NCT00512109). Observations from POISE provided the bases for the following VISION objectives: to determine the incidence of major vascular complications among a representative sample of adults undergoing noncardiac surgery (in POISE, the event rate was three times higher than had been predicted in previous studies); to develop a clinical model to predict major perioperative vascular complications (in POISE, the previous models underestimated risk); to determine the proportion of perioperative MIs that would probably go unrecognized without perioperative troponin monitoring; and to determine if these MIs independently influence a patient's risk of vascular death during the first year after surgery. VISION also involves many substudies, including a study of the effects of perioperative hypotension on major vascular complications and a biobank study that will provide insights into the pathophysiology, prediction and identification of perioperative MIs.
The POISE-2 trial is a factorial design (lowdose acetylsalicylic acid [ASA] v. placebo and low-dose clonidine v. placebo) that builds on the findings of POISE. We have completed the POISE-2 pilot study and have already randomized 650 of the 10 000 patients into the trial. Observational data from POISE showed that ASA was the perioperative drug associated with the largest statistically significant reduction in death. Clonidine lowers perioperative heart rates, which appeared to be a primary mechanism of how metoprolol CR prevented MIs in POISE. In the randomized controlled trials done to date, perioperative low-dose clonidine is associated with less clinically significant hypotension than was seen in the perioperative ß-blocker trials. [14] [15] [16] POISE showed that a perioperative ß-blocker results in both benefits and risks. Building on this knowledge, we have initiated POISE-2; hopefully, through low-dose clonidine, we can establish a way to obtain the benefits we saw in POISE while mitigating the risks. The knowledge gained through these trials will improve the safety of surgery for the 200 million adults worldwide who annually undergo noncardiac procedures.
